Ilene Gewirtz, MD, discusses her comprehensive approach to well visits and cancer screens and says education, if not expanded services, is key.
The addition of ramucirumab to second-line FOLFIRI resulted in a delay in disease progression and improved survival in metastatic colorectal cancer patients.
In this review we discuss the current treatment options in metastatic colon cancer, with a special focus on biologic agents and how molecular understanding guides treatment decisions.
The FDA has approved aflibercept (Zaltrap) to be used with the chemotherapy regimen FOLFIRI in the treatment of adults with metastatic colorectal cancer.
We review the evidence implicating a strong association between chronic inflammation and cancer, with an emphasis on colorectal and lung cancer.
Use of oral bisphsphonates ofr more than one year in postmenopausal women is associated with a 59 percent decrease in the relative risk of colorectoal cancer, according to a study published online Feb. 14 in the Journal of Clinical Oncology.
Neoadjuvant chemoradiation has become the favored adjuvant treatment for stages II and III rectal cancer. Compared to postoperative chemoradiation, this modality of treatment has been shown to be superior in terms of toxicity, local relapse, and sphincter-saving. This article will focus on the evolution of neoadjuvant chemotherapy over the past 2 decades, current acceptable neoadjuvant standards, and current investigational regimens.
Several developments in the past few years have incrementally progressed
the field and provided additional insights into the management
of advanced colorectal cancer. This review discusses the components
of current cytotoxic chemotherapy regimens for advanced colorectal
cancer: fluorouracil (5-FU), capecitabine (Xeloda), irinotecan
(Camptosar), and oxaliplatin (Eloxatin). The equivalence of several
front-line regimens has provided opportunities for increased tailoring
of therapies for individual patients. Preliminary data on
pharmacogenomics provides hope that we will be able to better match
patients with regimens and doses on the basis of individualized predictions
of toxicity and response. The importance of second-line therapy
in overall survival has again been highlighted; the best outcomes have
occurred in patients treated with 5-FU, oxaliplatin, and irinotecan in
combination with targeted therapies during the course of their disease.
Elderly patients are no exception to this finding. Combination regimens
and second-line therapy should be offered to elderly patients who
have adequate performance status and no contraindicated comorbid
conditions, without regard for their chronological age.